CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
Intra-Articular Hyaluronic Acid-Euflexxadevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01811654
NCT01811654N/ACompleted
CompareCT.gov

A Randomized, Pragmatic, Effectiveness Trial Evaluating Intra-articular Hyaluronan for the Symptomatic Treatment of Chronic Patellofemoral Pain Syndrome

NYU Langone Health·interventional·Posted Mar 14, 2013·Updated Feb 26, 2020

In Brief

A clinical study evaluating Intra-Articular Hyaluronic Acid-Euflexxa for Patellofemoral Pain Syndrome. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the safety and effectiveness of intra-articular hyaluronan (IAHA) injections for the treatment of symptomatic patellofemoral pain syndrome (PFPS) and determine if this treatment can provide incremental clinical benefits over standard care for patients with this diagnosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPatellofemoral Pain Syndrome
CountriesUnited States
CollaboratorsFerring Pharmaceuticals

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 14, 2013
Enrollment StartApr 1, 2013
Primary CompletionDec 7, 2016
Study CompletionMar 4, 2017
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 13.3 years ago

Interventions

Intra-Articular Hyaluronic Acid-Euflexxadevice

IAHA was approved by the FDA in 1997 as a synovial fluid replacement device to help relieve the pain associated with knee osteoarthritis (OA) in patients who fail to respond adequately to conservative treatment and simple analgesics. In this study, IAHA, specifically Euflexxa, will be used off-label to determine whether patients afflicted with PFPS will experience similar analgesic effects as seen in those with OA.